In agreement with this concept, celecoxib reduced the clonogenic potential of TKI-resistant CML cells (including cell lines carrying the T315I BCR-ABL mutation) and synergized with imatinib upon co-treatment of TKI-responsive cells. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.